Gensia Sicor Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc.

Allergan, Inc.

Sicor Inc.

Allergan Pharmaceuticals

Gensia Sincor Inc.

Dorla Mirejovsky

Guru Reddy

Luigi Lenaz

Bastiaan Nuijen

Ernie Pfadenhauer

Jos H Beijnen

Dilip R Ashtekar

Liananingsih Tanudarma

John Y Park

James N Cook

Peter Lindsay MacDonald

Steven S Matsumoto

Harun Takruri

Michael Burkhart

Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

Bladder cancer treatment and methods

This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration of fludarabine phosphate in the composition may be between about 0.5 mg/mL and about 50 mg/mL. The pH of the composition may be between about 5.5 and about 7.1.

Aqueous fludarabine phosphate composition

This invention is directed towards a ready-to-use aqueous composition of ifosfamide. In one embodiment, the invention is directed to an aqueous ifosfamide composition which comprises ifosfamide, a pharmaceutically acceptable buffer, and water. The concentration of ifosfamide in the composition may be between about 40 mM and about 400 mM. The concentration of buffer in the composition may be between about 10 mM and about 260 mM. The molar ratio of ifosfamide to buffer may be between about 0.5:1 to about 20:1. The pH of the composition may be between about 4 and about 8.

Aqueous ifosfamide composition

The invention includes a packaged liquid composition of a pamidronate alkaline salt in a sealed storage vessel having an inner surface which is non-reactive with the pamidronate alkaline salt composition.

Injectable pamidronate disodium

Sterile pharmaceutical compositions for parenteral administration containing 2,6-diisopropylphenol (propofol) are described for use as anesthetics. The compositions comprise an oil-in-water emulsion of propofol additionally comprising an amount of sulfite sufficient to prevent significant growth of microorganisms for at least 24 h after adventitious contamination.

Propofol composition containing sulfite

Methods and compositions for inhibiting the formation of proteinaceous and/or lipid deposits on a contact lens are disclosed. In one embodiment, the present method comprises contacting a contact lens being worn in a mammalian eye with at least one ophthalmically acceptable antioxidant component in an amount effective to inhibit the formation of at least one of proteinaceous deposits and lipid deposits on the contact lens in the eye.

Methods and compositions for inhibiting deposit formation on contact

Compositions and methods useful for enhancing the transdermal and transmembrane drug delivery of topical and systemic agents. The compositions and methods comprise the active agent together with an effective amount of certain amides of heterocyclic amines as defined herein as penetration enhancers and topically administering to human or animal skin or other membranes the resulting compositions.

Growing community of inventors

Irvine, CA, United States of America

Dorla Mirejovsky